Plant-derived Zerumbone and ICG Co-loaded Microneedle Patch System: A Novel Strategy for NIR-triggered Synergistic Chemo-Photothermal Therapy of Melanoma

Qing Zhu, Kaiyi Zhang, Bin Wang, Jie Lv, Huijuan Wang, Jiaqing Zhao, Dongxue Wang, Yue Yao, Linxi Zeng, Xiang Bai, Feng Zhao, Guoqiang ZhangResearch Square 2025 · DOI

Introduction

Melanoma is the most aggressive form of skin cancer, characterized by high metastatic potential and a significant mortality rate. While surgical excision is the standard primary treatment, it often fails to eliminate all malignant cells, leading to local recurrence. Conventional systemic chemotherapy faces two major hurdles: significant off-target toxicity and the poor physicochemical properties of many potent compounds. For instance, the ginger-derived sesquiterpenoid Zerumbone (ZER) is poorly water-soluble, while the photothermal agent Indocyanine Green (ICG) is prone to rapid degradation and aggregation. To overcome these barriers, researchers have developed a transdermal delivery platform designed to deliver these agents directly into the tumor microenvironment.

System Design and Methodology

The researchers developed a multi-stage delivery system that combines nanotechnology with microneedle engineering to ensure localized, synergistic therapy.

Schematic representation of the ZER-ICG@DMN patch fabrication and its synergistic therapeutic mechanism against melanoma.

As illustrated in the figure above, the process begins with the encapsulation of ZER and ICG within self-assembling mPEG-PLA polymeric micelles. This nanocarrier approach solves the solubility issues of ZER and stabilizes ICG. These micelles are then loaded into the tips of pyramid-shaped dissolvable microneedles (DMNs) made of Hyaluronic Acid (HA). These needles, approximately 507 µm in height, are designed to penetrate the skin's outer barrier (the stratum corneum) to a depth of ~280 µm. Once inserted, the HA matrix dissolves within five minutes, releasing the therapeutic payload directly at the tumor site.

Synergistic Therapeutic Mechanism

The system utilizes a triple-threat mechanism triggered by an 808 nm Near-Infrared (NIR) laser:

  1. Chemotherapy: ZER induces apoptosis (programmed cell death) by disrupting mitochondrial membrane potential.
  2. Photothermal Therapy (PTT): Upon NIR irradiation, ICG converts light into localized heat (reaching ~56°C), effectively "cooking" the cancer cells.
  3. Photodynamic Therapy (PDT): The NIR trigger also causes ICG to produce Reactive Oxygen Species (ROS), which further damage the tumor cells.

Key Results and Insights

The study utilized B16F10 and A375 melanoma cell lines for in vitro testing and BALB/c nude mice for in vivo efficacy and safety assessments.

  • Unprecedented Tumor Inhibition: The combination of ZER-ICG@DMNs and NIR laser treatment achieved a 99.35% Tumor Inhibition Rate (IRT). In the combination group, 3 out of 5 mice showed complete tumor ablation.
  • Mitochondrial Targeting: The ZER-ICG micelles were shown to specifically accumulate in the mitochondria, triggering the intrinsic pathway of cell suicide.
  • Superior Safety Profile: Unlike systemic chemotherapy, this localized approach showed no damage to major organs (heart, liver, spleen, lungs, and kidneys) via H&E staining. Blood biochemical markers (ALT, AST, BUN) remained within normal ranges, confirming minimal systemic toxicity.
  • Immune Modulation: The treatment also led to a downregulation of F4/80, suggesting a potential reduction in pro-tumor M2 macrophages within the tumor microenvironment.

Conclusion and Future Outlook

The ZER-ICG@DMN patch offers a highly effective, localized, and minimally invasive strategy for treating superficial malignant tumors. By bypassing systemic circulation, the system maximizes therapeutic impact while virtually eliminating side effects. Future work will focus on optimizing the system for sustained drug release and exploring methods to apply this NIR-triggered technology to deeper-seated malignancies.

Summary updated

Abstract

<title>Abstract</title> Melanoma is an aggressive form of skin cancer arising from melanocytes, noted for its high metastatic potential and elevated mortality rate. Conventional treatment approaches are often limited by nonspecific systemic drug distribution, which can result in undesirable adverse effects and premature drug degradation. In this study, we report the development of a microneedle (MN)-mediated delivery platform, incorporating self-assembling polymeric micelles, combining a dissolvable MN patch with polymeric micelles designed to prevent ICG aggregation and co-encapsulate ZER and ICG, and enable combined chemotherapy and photothermal therapy against melanoma. These nanocarriers, referred to as ZER-ICG-polymer micelles, co-encapsulate Zerumbone (ZER)—a lipophilic sesquiterpenoid—and indocyanine green (ICG), a well-known photothermal agent. In vitro cytotoxicity assessments and intracellular distribution studies confirm a marked synergistic therapeutic effect under NIR light exposure, facilitating localized thermal ablation of melanoma cells. In vivo experiments using melanoma-bearing mice demonstrate that a single application of the ZER-ICG-loaded dissolvable microneedle patch, coupled with NIR irradiation, achieves potent photothermal performance and robust tumor growth inhibition, while inducing minimal systemic toxicity and negligible side effects. These findings highlight the promising potential of this transdermal delivery system for the treatment of superficial malignant tumors.
BibTeX
@inproceedings{zhu2025plant,
  author = {Qing Zhu and Kaiyi Zhang and Bin Wang and Jie Lv and Huijuan Wang and Jiaqing Zhao and Dongxue Wang and Yue Yao and Linxi Zeng and Xiang Bai and Feng Zhao and Guoqiang Zhang},
  title = {{Plant-derived Zerumbone and ICG Co-loaded Microneedle Patch System: A Novel Strategy for NIR-triggered Synergistic Chemo-Photothermal Therapy of Melanoma}},
  booktitle = {Research Square},
  year = {2025},
  doi = {10.21203/rs.3.rs-7924988/v1},
}
Figure